Most health insurance plans do not cover intravenous ketamine infusions for depression or other psychiatric conditions. IV ketamine for depression is considered an off-label use -- while ketamine is FDA-approved as an anesthetic, it has not received FDA approval specifically for depression treatment via IV infusion. As a result, the majority of patients pay out of pocket, with costs ranging from $400 to $800 per infusion. However, FDA-approved intranasal esketamine (Spravato) does have insurance coverage from many major carriers, though with significant restrictions.
Why IV Ketamine Is Not Covered
Insurance coverage decisions are closely tied to FDA approval status. Although there is substantial clinical evidence supporting IV ketamine for treatment-resistant depression, the IV formulation has not gone through the specific FDA approval process for this indication. Generic ketamine is inexpensive as a raw pharmaceutical (often <$10 per dose), which means no pharmaceutical company has the financial incentive to fund the large-scale Phase III clinical trials required for a new FDA indication. Without that formal approval, insurance companies classify IV ketamine infusions as experimental or investigational for psychiatric use and deny coverage.
Some patients have had success obtaining partial reimbursement through out-of-network mental health benefits, particularly when their provider documents a history of treatment-resistant depression and multiple failed medication trials. However, this is not guaranteed and varies significantly by plan and insurer.
Spravato (Esketamine) Coverage
Intranasal esketamine (brand name Spravato), manufactured by Janssen Pharmaceuticals, received FDA approval in 2019 for treatment-resistant depression and in 2020 for major depressive disorder with suicidal ideation. Because it is FDA-approved for these specific indications, many commercial insurance plans and Medicare provide coverage, though typically with prior authorization requirements and step-therapy criteria.
To qualify for Spravato coverage, patients generally must demonstrate failure of at least two adequate antidepressant trials. The medication must be administered in a certified healthcare setting with 2-hour post-dose monitoring under the FDA's Risk Evaluation and Mitigation Strategy (REMS) program. Even with insurance, copays and coinsurance can be substantial, though the manufacturer offers a patient assistance program.
Other Financial Options
Patients paying out of pocket for IV ketamine can explore several strategies to manage costs. Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can generally be used for ketamine treatment prescribed by a licensed provider. Some clinics offer payment plans or package pricing for the initial 6-infusion course. Patients should also request superbills (detailed receipts with medical codes) that can be submitted to insurance for potential out-of-network reimbursement.
For more on practical treatment considerations, see the Complete Guide to Low-Dose Ketamine Therapy.
References
- FDA: Spravato (Esketamine) Approval Information — FDA approval details and REMS program requirements for esketamine
- NIMH: Depression Treatment — National Institute of Mental Health depression treatment overview
- MedlinePlus: Esketamine Nasal Spray — National Library of Medicine drug information for FDA-approved esketamine
Share